However, the emergence of chemoresistance, peripheral neuropathy, nephrotoxicity, and hepatorenal toxicity to paclitaxel has posed significant challenges in cervical cancer treatment.[42] Here we showed that silence of either lncTUBA3FP or ESCO1 enhanced the sensitivity of cervical cancer cells to paclitaxel, as evidenced by reduced tumorigenesis and increased ferroptosis levels. This evidence concerns the gene ESCO1 and cervical cancer.